The $1.6 Billion Eucalyptus Exit Is Worth Celebrating – but Here’s Why Female Founders Are Also Shaking Their Heads

Why It Matters

The gender‑biased founder composition can shape product design, patient trust, and overall equity in healthcare innovation, while systemic VC disparities continue to block women entrepreneurs from solving women’s health challenges.

Key Takeaways

• Eucalyptus sold for $1.6 billion, marking a digital‑health milestone in Australia
• Women use GLP‑1 drugs 1.7 × more than men, driving demand
• Only 2 % of Australian VC funding goes to all‑female founding teams
• Male‑only founder teams dominate late‑stage funding for women‑focused health products

Pulse Analysis

The $1.6 billion sale of Eucalyptus marks one of the biggest exits in Australia’s digital‑health arena. The company built a tele‑medicine platform around GLP‑1 drugs such as Ozempic and Wegovy, which have surged in popularity for weight‑loss and diabetes management. In the United States, women are roughly 1.7 times more likely to be prescribed these agents, a trend echoed in Australian prescribing data. By tapping a market where female patients dominate, Eucalyptus generated rapid revenue growth and attracted heavyweight investors, culminating in a valuation that rivals global health unicorns.

Yet the boardroom composition tells a different story. All four co‑founders are men, and the venture‑capital ecosystem that funded them reflects a broader Australian pattern: only about 2 % of VC dollars flow to all‑female founding teams, with virtually none reaching women‑led firms beyond Series B. This imbalance matters because founder gender influences product empathy, clinical trial design, and communication of side‑effects—areas where female users of GLP‑1s have voiced distinct concerns about body image and long‑term safety. When male‑only teams steer solutions for women, subtle blind spots can persist, potentially limiting adoption and trust.

The Eucalyptus deal therefore serves as a case study for the cost of overlooking diversity in health‑tech entrepreneurship. Greater inclusion of women at the founder and board level could yield products that better address emotional and psychosocial dimensions of treatment, improving adherence and outcomes. Policymakers and limited partners are beginning to tie capital to gender‑balanced teams, and accelerators focused on women‑led health startups are emerging. If the funding pipeline shifts, the next generation of digital‑health unicorns may be built by the very patients they aim to serve, delivering more nuanced and equitable care.